Adherence with proton pump inhibitor therapy, by continuously taking nonsteroidal anti-inflammatory drugs


Cite item

Full Text

Abstract

Aim. To estimate the impact of adherence with proton pump inhibitor (PPI) therapy on the incidence of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy (NSAID gastropathy) in patients with rheumatoid arthritis (RA). Subjects and methods. PPI pharmacotherapy adherence was estimated using the Medication Adherence Questionnaire (MAQ) in 92 patients with RA, including 32 patients did not take a PPI and 60 used a PPI. The groups were matched for age, disease duration, and used NSAIDs. All those asked underwent video esophagogastroduodenoscopy. Results. According to the data of MAQ survey, low, moderate, and high adherence subgroups could be identified among the patients treated with a PPI. NSAID gastropathy was detected in 43.8% of the patients taking no PPI, in 50% of those with low PPI treatment adherence, in 12.5% with moderate adherence, and in 4.5% with high adherence. In the patients with low adherence to PPI therapy, NSAID gastropathy was recorded 11 times more frequently than in those with high adherence (c2=7.77; p=0.005). This condition occurred in 28.6% of the patients taking NSAID without preventively using a PPI in the absence of risk factors for NSAID gastropathy. Conclusion. Only 36.7% patients who had been recommended to use a PPI for the prevention of NSAID gastropathy strictly observed their doctor’s directions. Low PPI pharmacotherapy adherence may serve as an additional risk factor for NSAID gastropathy in patients in whom preventive antisecretory therapy used in combination with NSAID is indicated.

References

  1. Sturkenboom M.C., Burke T.A., Tangelder M.J., Dieleman J.P., Walton S., Goldstein J.L. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003; 18 (11—12): 1137—1147.
  2. Sturkenboom M.C., Burke T.A., Dieleman J.P., Tangelder M.J., Lee F., Goldstein J.L. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003; 42 (3): 23—31.
  3. Goldstein J.L., Howard K.B., Walton S.M., McLaughlin T.P., Kruzikas D.T. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complication. Clin Gastroenterol Hepatol 2006; 4 (11): 1337—1345.
  4. van Soest E.M., Sturkenboom M.C., Dieleman J.P., Verhamme K.M., Siersema P.D., Kuipers E.J. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007; 26 (2): 265—275.
  5. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Artritis Rheum 1988; 31 (3): 315—324.
  6. Chan F.K., Abracham N.S., Scheiman J.M., Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008; 103 (11): 2908—2918.
  7. Пиманов С.И., Семенова Е.В., Макаренко Е.В., Руселик Е.А. Гастродуоденальные язвы, вызываемые антиагрегантными и нестероидными противовоспалительными препаратами: профилактика по новым рекомендациям. Cons med Приложение. Гастроэнтерология 2009; 11: 13—20.
  8. Bhatt D.L., Sheiman J., Abraham N.S., Antman E.M., Chan F.K., Furberg C.D., Johnson D.A., Mahaffey K.W., Quigley E.M.; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents ACCF/ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118 (18): 1894—1909.
  9. Lanza F.L., Chan F.K., Quigley E.M. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728—738.
  10. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24 (1): 67—74.
  11. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М: МедиаСфера; 2002: 227—253.
  12. Smalley W., Stein C.M., Arbogast P.G., Eisen G., Ray W.A., Griffin M. Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002; 46 (8): 2195—2200.
  13. van Soest E.M., Valkhoff V.E., Mazzaglia G., Schade R., Molokhia M., Goldstein J.L., Hernández-Díaz S., Trifirò G., Dieleman J.P., Kuipers E.J., Sturkenboom M.C. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011; 60 (12): 1650—1659.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies